COPD management has progressively centered on bronchodilator-based regimens, with Long-acting Muscarinic Antagonists (LAMAs) and Long-acting Beta-agonists (LABAs) forming the therapeutic core. Dual LAMA/LABA therapy is standard for moderate disease, while triple therapy with Inhaled Corticosteroids (ICS) is reserved for severe cases or frequent exacerbators. The current development COPD clinical trials landscape reflects an inflection point in treatment strategy, with a shift from conventional bronchodilators toward targeted therapies and biologics.
What is the Market Outlook of DUPIXENT With its “First-ever Biologic” Advantage in COPD?
Even though good therapie...
